Skip To Main Content
This website is intended exclusively for healthcare professionals residing and/or working in Kuwait.
Campus
Campus

Dyslipidemia

Learn about the latest trends, discover events and innovations in the changing world of dyslipidemia disease.

Science in Dyslipidemia Disease

Get a 360º view and stay up-to-date on cardiovascular disease with content selected for you

Approach for Patients with PAD and T2D: Focus on LDL-C Control
  • Dyslipidemia

Approach for Patients with PAD and T2D: Focus on LDL-C Control

Learn More
Approach for Patients with CAD: Focus on LDL-C Control
  • Dyslipidemia

Approach for Patients with CAD: Focus on LDL-C Control

Learn More
Cardiovascular diseases (CVDs) are the leading cause of death globally<sup>1</sup>
  • Dyslipidemia

Cardiovascular diseases (CVDs) are the leading cause of death globally1

According to the World Health Organization, an estimated 17.9 million people died from CVDs in 2019, representing 32% of all global deaths1. Of these deaths, 85% were due to myocardial infarction or stroke1.

A CV event is a highly traumatic experience for patients and their families2. It takes a heavy emotional toll, brings widespread disability and significantly impedes quality of life3,4.

Learn More
Lipid Management in Patients with Diabetes Mellitus
  • Dyslipidemia

Lipid Management in Patients with Diabetes Mellitus

Learn More
Prospective evaluation of lipid management following ACS in Saudi Arabia (ACOSYM Study)
  • Dyslipidemia

Prospective evaluation of lipid management following ACS in Saudi Arabia (ACOSYM Study)

Learn More
Acute LDL-C Reduction Post ACS: Strike Early and Strike Strong: From Evidence to Clinical Practice
  • Dyslipidemia

Acute LDL-C Reduction Post ACS: Strike Early and Strike Strong: From Evidence to Clinical Practice

Learn More
Management of Patients With Very High Cardiovascular Risk Eligible for PCSK9 Inhibitor Treatment: 1-year Outcomes of The PERI-DYS Study
  • Dyslipidemia

Management of Patients With Very High Cardiovascular Risk Eligible for PCSK9 Inhibitor Treatment: 1-year Outcomes of The PERI-DYS Study

Learn More
Prospective evaluation of lipid management following acute coronary syndrome in Saudi Arabia
  • Dyslipidemia

Prospective evaluation of lipid management following acute coronary syndrome in Saudi Arabia

Learn More

Inspiration and innovation

Get inspired and stay at the forefront of innovation with the following resources

Approach for Patients with PAD and T2D: Focus on LDL-C Control
  • Dyslipidemia

Approach for Patients with PAD and T2D: Focus on LDL-C Control

Learn More
Approach for Patients with CAD: Focus on LDL-C Control
  • Dyslipidemia

Approach for Patients with CAD: Focus on LDL-C Control

Learn More
Cardiovascular diseases (CVDs) are the leading cause of death globally<sup>1</sup>
  • Dyslipidemia

Cardiovascular diseases (CVDs) are the leading cause of death globally1

According to the World Health Organization, an estimated 17.9 million people died from CVDs in 2019, representing 32% of all global deaths1. Of these deaths, 85% were due to myocardial infarction or stroke1.

A CV event is a highly traumatic experience for patients and their families2. It takes a heavy emotional toll, brings widespread disability and significantly impedes quality of life3,4.

Learn More
Lipid Management in Patients with Diabetes Mellitus
  • Dyslipidemia

Lipid Management in Patients with Diabetes Mellitus

Learn More
Prospective evaluation of lipid management following ACS in Saudi Arabia (ACOSYM Study)
  • Dyslipidemia

Prospective evaluation of lipid management following ACS in Saudi Arabia (ACOSYM Study)

Learn More
Acute LDL-C Reduction Post ACS: Strike Early and Strike Strong: From Evidence to Clinical Practice
  • Dyslipidemia

Acute LDL-C Reduction Post ACS: Strike Early and Strike Strong: From Evidence to Clinical Practice

Learn More
Management of Patients With Very High Cardiovascular Risk Eligible for PCSK9 Inhibitor Treatment: 1-year Outcomes of The PERI-DYS Study
  • Dyslipidemia

Management of Patients With Very High Cardiovascular Risk Eligible for PCSK9 Inhibitor Treatment: 1-year Outcomes of The PERI-DYS Study

Learn More
Prospective evaluation of lipid management following acute coronary syndrome in Saudi Arabia
  • Dyslipidemia

Prospective evaluation of lipid management following acute coronary syndrome in Saudi Arabia

Learn More

Events

Stay up to date and register for the latest events and view webinar recordings.

Dyslipidemia Webinars: Optimizing Dyslipidemia management​
  • Dyslipidemia

Dyslipidemia Webinars: Optimizing Dyslipidemia management​

Learn More